Meitav Investment House Ltd. Reduces Stock Position in Cellebrite DI Ltd. $CLBT

Key Points

• Meitav Investment House Ltd. reduced its stake in Cellebrite DI Ltd. by 2.2%, holding 1,454,846 shares valued at approximately $23.3 million after selling 33,435 shares.
• Institutional investors currently own 45.88% of Cellebrite DI, with notable increases in positions from firms like Voss Capital and Invesco during the first quarter.
• Analysts maintain a consensus rating of "Moderate Buy" with a target price of $21.75, although firms like Lake Street Capital and Needham lowered their target prices for the stock in recent reports.

Meitav Investment House Ltd. lowered its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 2.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,454,846 shares of the company's stock after selling 33,435 shares during the period. Meitav Investment House Ltd. owned about 0.61% of Cellebrite DI worth $23,278,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Voss Capital LP boosted its position in Cellebrite DI by 18.6% during the 1st quarter. Voss Capital LP now owns 3,843,602 shares of the company's stock valued at $74,681,000 after buying an additional 603,602 shares during the period. Invesco Ltd. lifted its position in shares of Cellebrite DI by 122.1% in the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after purchasing an additional 1,811,757 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Cellebrite DI in the 1st quarter worth about $60,939,000. Handelsbanken Fonder AB lifted its position in shares of Cellebrite DI by 749.9% in the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after purchasing an additional 1,340,000 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Cellebrite DI in the 1st quarter worth about $22,428,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on CLBT. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Friday, September 26th. Lake Street Capital dropped their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Cellebrite DI in a research report on Saturday, September 27th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.75.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $18.80 on Tuesday. The firm has a market cap of $4.50 billion, a P/E ratio of -24.74, a P/E/G ratio of 3.38 and a beta of 1.29. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The firm has a 50-day simple moving average of $16.33 and a two-hundred day simple moving average of $16.95.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same period last year, the business earned $0.10 EPS. Cellebrite DI's revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.